
## Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA/S1PR2/ZBP1/p-MLKL axis

Shen Yang<sup>1,2</sup>#, Na Chang<sup>1</sup>#, Weiyang Li<sup>1</sup>#, Ting Yang<sup>2</sup>, Renmin Xue<sup>1</sup>, Jing Liu<sup>1</sup>, Li Zhang<sup>3</sup>, Xingfeng Yao<sup>4</sup>, Yajun Chen<sup>5</sup>, Huanmin Wang<sup>6</sup>, Lin Yang<sup>1</sup>, Jinshi Huang<sup>2</sup>\*, Liying Li<sup>1</sup>\*


## Supplementary Table 1. The comparison of clinical characteristics between biliary atresia and control groups.

Clinical characteristics	Biliary atresia $(n = 31)$	Control $(n = 20)$	<i>p</i> value
Boys (n, %)	16 (51.61)	12 (60.00)	0.557
Age (months, median, IQR)	2 (1, 3)	21 (12, 33)	< 0.001
Aspartate aminotransferase	303.50 (215.70, 371.70)	85.50 (48.90, 722.20)	< 0.001
(U/L, median, IQR)			
Alanine aminotransferase	207.30 (136.00, 267.40)	39.10 (20.50, 263.50)	< 0.001
(U/L, median, IQR)			
Total bilirubin	168.70 (140.23, 203.84)	8.04 (6.43, 13.55)	< 0.001
(µmol/L, median, IQR)			
Direct bilirubin	125.75 (92.11, 147.72)	2.62 (0.79, 4.46)	< 0.001
(µmol/L, median, IQR)			
Indirect bilirubin	52.16 (44.22, 87.40)	7.15 (5.75, 12.26)	< 0.001
(µmol/L, median, IQR)			
Total bile acid	138.54 (102.22, 214.20)	6.33 (3.52, 7.64)	< 0.001
(µmol/L, median, IQR)			
γ-GT (U/L, median, IQR)	786.40 (504.00, 1517.10)	42.60 (32.70, 93.60)	< 0.001




Supplementary Figure 1. The Pathological changes of BA livers and RIPK1/RIPK3 expressions in BDL or BMDMs.

A. Representative images of H&E staining in normal adjacent non-tumor livers (HC) and biliary atresia (BA) livers. Scale bar: 50  $\mu$ m. **B.** Western blot analysis for p-RIPK1 and p-RIPK3 in the liver tissues from BDL (n=8) and Sham mice (n=5). **C.** Mouse BMDMs were treated with 100  $\mu$ mol/L sodium glycodeoxycholate (GDCA) for 6 hours, with or without treatment of TSZ (TNF $\alpha$  plus Smac mimetic and a pan-caspase inhibitor z-VAD-FMK) for 6 hours. Western blot analysis for p-RIPK1 and p-RIPK3 in mouse BMDMs. **D.** Effects of *Zbp1* siRNA on p-RIPK1 and p-RIPK3 protein expression in mouse BMDMs. Bolts of p-RIPK1 or p-RIPK3 were normalized to RIPK1 or RIPK3, respectively. Data are presented as the mean  $\pm$  SEM. \* *p*<0.05, \*\* *p*<0.01 (versus control).



Supplementary Figure 2. The efficiency of siRNAs in mouse BMDMs

A-C. The efficiency of *S1pr2* (A), *Zbp1* (B) or MLKL (C) knockdown by the siRNA in mouse BMDMs. \*\* p < 0.01, \*\*\* p < 0.001 (versus control).



Supplementary Figure 3. Necroptosis inhibitor (Necrosulfonamide, NSA) alleviates inflammation /fibrosis in BDL liver.

A. The schedule of mouse model. **B**. Serum AST and ALT levels were detected in BDL livers with or without NSA treatment. **C**. Representative images of H&E staining. Black dashed: inflammation area. Scale bars: 50  $\mu$ m. **D**. mRNA expressions of fibrosis markers (*Acta2*, *Col1a1* and *Col3a1*) were detected by qRT-PCR. **E**. Western blot analysis for Col I and  $\alpha$ -SMA in the liver tissues from BDL mouse livers treated with or without NSA. **F**. Representative images of Masson staining. White

dashed: collagen deposition area. Scale bars: 50  $\mu$ m. Data are presented as the mean  $\pm$  SEM. \* *p*<0.05, \*\* *p*<0.01, \*\*\* *p*<0.001 (versus control). # *p*<0.05, ## *p*<0.01 (versus BDL alone).